REMIT: A trial looking at radiotherapy as a priming treatment before CAR-T therapy in DLBCL

This phase two trial is testing radiotherapy as a bridging method prior to CAR-T therapy in people with diffuse large B-cell lymphoma (DLBCL) which has either not responded to treatment (refractory) or returned after treatment (relapsed).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04726787

Trial aim and background 

The aim of this trial is to investigate radiotherapy as a bridging/priming treatment prior to the CAR-T therapy Tisagenlecleucel. 

CAR-T therapy involves collecting the patient’s own immune cells called T cells, modifying them so that they can recognise and destroy the cancer cells and then infusing them back into the person.

Participants in this trial will initially have a PET-CT scan to establish how much disease they have, and how much radiotherapy they require. They will then have the first stage of CAR-T therapy which involves removing their T cells, leukapheresis. As soon as this has happened radiotherapy will commence, aimed at the disease areas. During this time the CAR-T cells will be being produced in the lab, ready for infusion back into the patient 14 days after the last course of radiotherapy.

The main aim is to see whether there is any delay in the CAR-T therapy when radiotherapy is used as a bridging treatment, as well as seeing how effective it is at establishing a complete or partial response in patients.

Who can enter

Adults aged over 18 with DLBCL which has not responded to, or relapsed after, two immunochemotherapy treatments, and are able to receive Tisagenlecleucel may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • St James’s University Hospital, Leeds
  • Kings College Hospital, London
  • Freeman Hospital, Newcastle

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://beta.clinicaltrials.gov/study/NCT04726787

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.